<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04148664</url>
  </required_header>
  <id_info>
    <org_study_id>SHORT-AF</org_study_id>
    <nct_id>NCT04148664</nct_id>
  </id_info>
  <brief_title>A Trial of High Power-Short Duration Versus Standard Power-Long Duration Radiofrequency Ablation for Treatment of Atrial Fibrillation</brief_title>
  <acronym>Short-AF</acronym>
  <official_title>SHORT-AF: A Randomized Trial of High Power-Short Duration Versus Standard Power-Long Duration Radiofrequency Ablation for Treatment of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, randomized controlled study to compare overall clinical outcomes&#xD;
      between High Power Short Duration (HPSD) and standard radiofrequency (RF) ablation settings&#xD;
      for Atrial Fibrillation (AF) ablation in the treatment of subjects with paroxysmal or&#xD;
      persistent Atrial Fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary vein isolation using radiofrequency (RF) ablation is a widely used treatment&#xD;
      strategy for atrial fibrillation. Peri-procedural complications rates are estimated at&#xD;
      between 1.5 - 6% with the two most feared complications being stroke and atrial-esophageal&#xD;
      fistula. The risk of these complications increases with (1) longer left atrial dwell times&#xD;
      with greater potential for clot formation and (2) esophageal heating during delivery of&#xD;
      radiofrequency energy. 'High-power short-duration' (HPSD) is an increasingly utilized&#xD;
      strategy to decrease procedure duration and minimize the risk of these complications.&#xD;
      Potential mechanisms for benefit include: (1) shorter left atrial dwell times due to more&#xD;
      efficient lesion delivery (2) rapid, but more controlled, resistive tissue heating, which&#xD;
      avoids deeper, passive conductive heating that can reach the esophagus and cause injury.&#xD;
      Moreover, HPSD may improve lesion efficacy and durability due to less recover of excitability&#xD;
      after ablation. Despite being widely used and several retrospective studies, there have been&#xD;
      no prospective randomized trials comparing outcomes between HPSD and standard RF ablation&#xD;
      settings. Moreover, the investigators are interested to see if a shorter procedure (less time&#xD;
      in the left atrium) is associated with a lower rate of silent cerebral infarctions (which are&#xD;
      occasionally seen on MRI brain post RF ablation - their clinical significance is unclear).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 3, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Actual">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a multi-center prospective single-blinded randomized controlled trial. Enrollment of 60 subjects undergoing clinically-indicated AF ablation is planned with 1:1 block randomization (standard 'low power' RF settings n=30, HPSD n=30 and allowing for 10 drop-outs / consent withdrawals). Follow-up will be over 12 months.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ablation Duration</measure>
    <time_frame>During Ablation</time_frame>
    <description>RF ablation duration from start of first pulmonary vein isolation lesion to end of last lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum esophageal temperature</measure>
    <time_frame>During ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum esophageal temperature rise</measure>
    <time_frame>During ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Atrial Fibrillation</measure>
    <time_frame>assessed at 6 and 12 months post-ablation</time_frame>
    <description>&gt;30 secs using Ziopatch, 1 year off or on previously ineffective antiarrhythmic drugs (AADs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Atrial Fibrillation</measure>
    <time_frame>assessed at 6 and 12 months post-ablation</time_frame>
    <description>&gt;30 secs using Ziopatch, 1 year off previously ineffective antiarrhythmic drugs (AADs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% pulmonary vein pairs isolated with first encirclement</measure>
    <time_frame>During Ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of radiofrequency lesions required for isolation/PV</measure>
    <time_frame>During Ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total left atrial radiofrequency (RF) time</measure>
    <time_frame>During Ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total procedure duration</measure>
    <time_frame>During Ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall complication rate</measure>
    <time_frame>During Ablation and up to 12 month follow up assessment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pleurisy</measure>
    <time_frame>At 1 week and 1 month assessment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pericardial effusion&gt;1cm</measure>
    <time_frame>During ablation or up to 30 days post ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pericardial tamponade requiring drainage</measure>
    <time_frame>During ablation or up to 30 days post ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total saline infused</measure>
    <time_frame>During Ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of asymptomatic cerebral emboli</measure>
    <time_frame>1 day post-ablation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Fibrillation Paroxysmal</condition>
  <condition>Atrial Fibrillation, Persistent</condition>
  <arm_group>
    <arm_group_label>Standard Catheter Settings</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 - Standard RF ablation settings</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Power Short Duration (HPSD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 - High power short duration RF</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter ablation with Standard RF ablation settings</intervention_name>
    <description>Standard RF ablation settings (n=30):&#xD;
Maximum 35W for 20-40 seconds, per operator standard.</description>
    <arm_group_label>Standard Catheter Settings</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter ablation with High Power Short Duration RF ablation settings</intervention_name>
    <description>High power short duration RF (n=30):&#xD;
Maximum 50 Watts for 5-15 seconds, per operator standard.</description>
    <arm_group_label>High Power Short Duration (HPSD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female â‰¥18 years of age at their pre-operative visit.&#xD;
&#xD;
          2. Patient is scheduled to have their first AF ablation&#xD;
&#xD;
          3. Paroxysmal or persistent AF&#xD;
&#xD;
          4. Written informed consent (and assent when applicable) obtained from subject or&#xD;
             subject's legal representative and ability for subject to comply with the requirements&#xD;
             of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior AF ablation&#xD;
&#xD;
          2. Stroke or transient ischemic attack (TIA) within the previous 6 months&#xD;
&#xD;
          3. Known esophageal ulcer or gastrointestinal (GI) bleed within prior 6 months&#xD;
&#xD;
          4. Intent to perform adjunctive left atrial ablation, including posterior wall isolation,&#xD;
             left atrial appendage isolation, mitral or other linear lesions.&#xD;
&#xD;
          5. Prior rheumatic heart disease or significant mitral stenosis&#xD;
&#xD;
          6. Mechanical mitral valve replacement&#xD;
&#xD;
          7. Long lasting persistent AF &gt; 1 year&#xD;
&#xD;
          8. Severe left ventricular systolic dysfunction, with LV ejection fraction LVEF&lt;35%&#xD;
&#xD;
          9. Prior left atrial appendage (LAA) occlusion device&#xD;
&#xD;
         10. Prior septal occlusion device&#xD;
&#xD;
         11. Pregnancy&#xD;
&#xD;
         12. Pacemaker, defibrillator or any contraindication to MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward P Gerstenfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief of Cardiac Electrophysiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Perino AC, Leef GC, Cluckey A, Yunus FN, Askari M, Heidenreich PA, Narayan SM, Wang PJ, Turakhia MP. Secular trends in success rate of catheter ablation for atrial fibrillation: The SMASH-AF cohort. Am Heart J. 2019 Feb;208:110-119. doi: 10.1016/j.ahj.2018.10.006. Epub 2018 Oct 29.</citation>
    <PMID>30502925</PMID>
  </reference>
  <reference>
    <citation>Kim TH, Park J, Uhm JS, Joung B, Lee MH, Pak HN. Pulmonary vein reconnection predicts good clinical outcome after second catheter ablation for atrial fibrillation. Europace. 2017 Jun 1;19(6):961-967. doi: 10.1093/europace/euw128.</citation>
    <PMID>27256420</PMID>
  </reference>
  <reference>
    <citation>Asbach S, Biermann J, Bode C, Faber TS. Early Heparin Administration Reduces Risk for Left Atrial Thrombus Formation during Atrial Fibrillation Ablation Procedures. Cardiol Res Pract. 2011;2011:615087. doi: 10.4061/2011/615087. Epub 2011 Jul 2.</citation>
    <PMID>21747989</PMID>
  </reference>
  <reference>
    <citation>Winkle RA, Mohanty S, Patrawala RA, Mead RH, Kong MH, Engel G, Salcedo J, Trivedi CG, Gianni C, Jais P, Natale A, Day JD. Low complication rates using high power (45-50 W) for short duration for atrial fibrillation ablations. Heart Rhythm. 2019 Feb;16(2):165-169. doi: 10.1016/j.hrthm.2018.11.031.</citation>
    <PMID>30712645</PMID>
  </reference>
  <reference>
    <citation>Leshem E, Zilberman I, Tschabrunn CM, Barkagan M, Contreras-Valdes FM, Govari A, Anter E. High-Power and Short-Duration Ablation for Pulmonary Vein Isolation: Biophysical Characterization. JACC Clin Electrophysiol. 2018 Apr;4(4):467-479. doi: 10.1016/j.jacep.2017.11.018. Epub 2018 Feb 2.</citation>
    <PMID>30067486</PMID>
  </reference>
  <reference>
    <citation>Nair KK, Shurrab M, Skanes A, Danon A, Birnie D, Morillo C, Chauhan V, Mangat I, Ayala-Paredes F, Champagne J, Nault I, Tang A, Verma A, Lashevsky I, Singh SM, Crystal E. The prevalence and risk factors for atrioesophageal fistula after percutaneous radiofrequency catheter ablation for atrial fibrillation: the Canadian experience. J Interv Card Electrophysiol. 2014 Mar;39(2):139-44. doi: 10.1007/s10840-013-9853-z. Epub 2013 Dec 7.</citation>
    <PMID>24317916</PMID>
  </reference>
  <reference>
    <citation>Nair KK, Danon A, Valaparambil A, Koruth JS, Singh SM. Atrioesophageal Fistula: A Review. J Atr Fibrillation. 2015 Oct 31;8(3):1331. doi: 10.4022/jafib.1331. eCollection 2015 Oct-Nov. Review.</citation>
    <PMID>27957213</PMID>
  </reference>
  <reference>
    <citation>Han HC, Ha FJ, Sanders P, Spencer R, Teh AW, O'Donnell D, Farouque O, Lim HS. Atrioesophageal Fistula: Clinical Presentation, Procedural Characteristics, Diagnostic Investigations, and Treatment Outcomes. Circ Arrhythm Electrophysiol. 2017 Nov;10(11). pii: e005579. doi: 10.1161/CIRCEP.117.005579. Review.</citation>
    <PMID>29109075</PMID>
  </reference>
  <reference>
    <citation>Bhaskaran A, Chik W, Pouliopoulos J, Nalliah C, Qian P, Barry T, Nadri F, Samanta R, Tran Y, Thomas S, Kovoor P, Thiagalingam A. Five seconds of 50-60 W radio frequency atrial ablations were transmural and safe: an in vitro mechanistic assessment and force-controlled in vivo validation. Europace. 2017 May 1;19(5):874-880. doi: 10.1093/europace/euw077.</citation>
    <PMID>27207815</PMID>
  </reference>
  <reference>
    <citation>Baher A, Kheirkhahan M, Rechenmacher SJ, Marashly Q, Kholmovski EG, Siebermair J, Acharya M, Aljuaid M, Morris AK, Kaur G, Han FT, Wilson BD, Steinberg BA, Marrouche NF, Chelu MG. High-Power Radiofrequency Catheter Ablation of Atrial Fibrillation: Using Late Gadolinium Enhancement Magnetic Resonance Imaging as a Novel Index of Esophageal Injury. JACC Clin Electrophysiol. 2018 Dec;4(12):1583-1594. doi: 10.1016/j.jacep.2018.07.017. Epub 2018 Sep 26.</citation>
    <PMID>30573123</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We are open to collaboration but do not plan to give our data to others.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

